Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.
Martin Wermke, MD
Advertisement
Martin Wermke, MD is the Group leader of the Thoracic Oncology Group, Professor for Experimental Cancer Therapy, Head of Early Clinical Trial Unit, and Head of Trial Management NCT Clinical Trial Center.
Articles by Martin Wermke, MD
Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Advertisement
Latest Updated Articles
Dr Wermke on the Efficacy and Safety of Obrixtamig With Topotecan in Advanced SCLCPublished: June 9th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5